[1] Holbrook A M, Pereira J A, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions[J]. Arch Intern Med, 2005, 165(10):1095-1106. [2] Kunze K L, Wienkers L C, Thummel K E, et al. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies[J]. Drug Metab Dispos, 1996, 24(4):414-421. [3] Kaminsky L S, Zhang Z Y. Human P450 metabolism of warfarin[J]. Pharmacol Ther, 1997, 73(1):67-74. [4] van der Elst K C, Span L F, van Hateren K, et al. Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole[J]. Antimicrob Agents Chemother, 2013, 57(10):4999-5004. [5] Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications[J]. Antimicrob Agents Chemother, 2009, 53(1):24-34. [6] Niwa T, Inoue-Yamamoto S, Shiraga T, et al. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes[J]. Biol Pharm Bull, 2005, 28(9):1813-1816. [7] Yamamoto H, Habu Y, Yano I, et al. Comparison of the effects of azole antifungal agents on the anticoagulant activity of warfarin[J]. Biol Pharm Bull, 2014, 37(12):1990-1993. [8] Miura M, Takahashi N, Kanno S, et al. Drug interaction of (S)-warfarin, and not (R)-warfarin, with itraconazole in a hematopoietic stem cell transplant recipient[J]. Clin Chim Acta, 2011, 412(21-22):2002-2006. |